Ken Griffin Vir Biotechnology, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$7.26 - $10.7 $78,408 - $115,559	10,800 Added 52.43%	31,400 $235,000
Q2 2024 Aug 14, 2024	SELL	$7.63 - $12.66 $57,225 - $94,950	-7,500 Reduced 26.69%	20,600 $183,000
Q1 2024 May 15, 2024	BUY	$8.6 - $11.9 $57,620 - $79,730	6,700 Added 31.31%	28,100 $284,000
Q4 2023 Feb 14, 2024	SELL	$7.76 - $10.29 $136,576 - $181,103	-17,600 Reduced 45.13%	21,400 $215,000
Q3 2023 Nov 14, 2023	SELL	$9.14 - $24.62 $50,270 - $135,410	-5,500 Reduced 12.36%	39,000 $365,000
Q2 2023 Aug 14, 2023	BUY	$23.2 - $27.29 $278,400 - $327,480	12,000 Added 36.92%	44,500 $1.09 Million
Q1 2023 May 15, 2023	SELL	$22.26 - $30.85 $371,742 - $515,195	-16,700 Reduced 33.94%	32,500 $756,000
Q4 2022 Feb 14, 2023	SELL	$19.96 - $28.22 $67,864 - $95,948	-3,400 Reduced 6.46%	49,200 $1.25 Million
Q3 2022 Nov 14, 2022	SELL	$18.26 - $31.1 $98,604 - $167,940	-5,400 Reduced 9.31%	52,600 $1.01 Million

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $979M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.